Many years ago, around the time when the US FDA was considering a “reevaluation” of the erythropoiesis-stimulating agents (ESAs) with a forthcoming advisory committee, the agency's dean of drug development Bob Temple was asked how the agency prepared for a panel meeting.
“I participate in a lot of these advisory committees," Temple said. "You have got to be careful. You don't want...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?